Cover Image
Market Research Report
Product code
997778

Autoimmune Disease Therapeutics

Published: | Global Industry Analysts, Inc. | 387 Pages | Delivery time: 1-2 business days

Price

Back to Top
Autoimmune Disease Therapeutics
Published: April 1, 2021
Global Industry Analysts, Inc.
Content info: 387 Pages
Delivery time: 1-2 business days
  • ALL
  • Description
  • Table of Contents
Description

Abstract:

Global Autoimmune Disease Therapeutics Market to Reach $139.4 Billion by 2027

Amid the COVID-19 crisis, the global market for Autoimmune Disease Therapeutics estimated at US$115.1 Billion in the year 2020, is projected to reach a revised size of US$139.4 Billion by 2027, growing at a CAGR of 2.8% over the analysis period 2020-2027. Anti-inflammatory, one of the segments analyzed in the report, is projected to record a 3.4% CAGR and reach US$75.5 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Antihyperglycemics segment is readjusted to a revised 2.7% CAGR for the next 7-year period.

The U.S. Market is Estimated at $31.1 Billion, While China is Forecast to Grow at 5.2% CAGR

The Autoimmune Disease Therapeutics market in the U.S. is estimated at US$31.1 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$28.2 Billion by the year 2027 trailing a CAGR of 5.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 0.7% and 2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 1.3% CAGR.

NSAIDs Segment to Record 2.3% CAGR

In the global NSAIDs segment, USA, Canada, Japan, China and Europe will drive the 2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$7.8 Billion in the year 2020 will reach a projected size of US$8.9 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$19.2 Billion by the year 2027, while Latin America will expand at a 3% CAGR through the analysis period.

Select Competitors (Total 138 Featured) -

  • Abbott Laboratories, Inc.
  • AbbVie, Inc.
  • Amgen, Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • Novartis International AG
  • Pfizer, Inc.
  • UCB SA
Table of Contents
Product Code: MCP-1829

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Autoimmune Disease Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Autoimmune Disease Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Autoimmune Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Anti-inflammatory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Anti-inflammatory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Anti-inflammatory by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Antihyperglycemics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Antihyperglycemics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Antihyperglycemics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for NSAIDs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Interferons by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Interferons by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Interferons by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Other Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Other Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Other Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Rheumatic Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Rheumatic Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Rheumatic Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Type 1 Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Type 1 Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Type 1 Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 25: World Current & Future Analysis for Multiple Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 26: World Historic Review for Multiple Sclerosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 27: World 15-Year Perspective for Multiple Sclerosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 28: World Current & Future Analysis for Inflammatory Bowel Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 29: World Historic Review for Inflammatory Bowel Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 30: World 15-Year Perspective for Inflammatory Bowel Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 31: World Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 32: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 33: World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 34: USA Current & Future Analysis for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 35: USA Historic Review for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 36: USA 15-Year Perspective for Autoimmune Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class for the Years 2012, 2020 & 2027
    • TABLE 37: USA Current & Future Analysis for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 38: USA Historic Review for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 39: USA 15-Year Perspective for Autoimmune Disease Therapeutics by Indication - Percentage Breakdown of Value Sales for Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 40: Canada Current & Future Analysis for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 41: Canada Historic Review for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: Canada 15-Year Perspective for Autoimmune Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class for the Years 2012, 2020 & 2027
    • TABLE 43: Canada Current & Future Analysis for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Canada Historic Review for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 45: Canada 15-Year Perspective for Autoimmune Disease Therapeutics by Indication - Percentage Breakdown of Value Sales for Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 46: Japan Current & Future Analysis for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Japan Historic Review for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 48: Japan 15-Year Perspective for Autoimmune Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class for the Years 2012, 2020 & 2027
    • TABLE 49: Japan Current & Future Analysis for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Japan Historic Review for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 51: Japan 15-Year Perspective for Autoimmune Disease Therapeutics by Indication - Percentage Breakdown of Value Sales for Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 52: China Current & Future Analysis for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 53: China Historic Review for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 54: China 15-Year Perspective for Autoimmune Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class for the Years 2012, 2020 & 2027
    • TABLE 55: China Current & Future Analysis for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: China Historic Review for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 57: China 15-Year Perspective for Autoimmune Disease Therapeutics by Indication - Percentage Breakdown of Value Sales for Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 58: Europe Current & Future Analysis for Autoimmune Disease Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 59: Europe Historic Review for Autoimmune Disease Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 60: Europe 15-Year Perspective for Autoimmune Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 61: Europe Current & Future Analysis for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Europe Historic Review for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 63: Europe 15-Year Perspective for Autoimmune Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class for the Years 2012, 2020 & 2027
    • TABLE 64: Europe Current & Future Analysis for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Europe Historic Review for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 66: Europe 15-Year Perspective for Autoimmune Disease Therapeutics by Indication - Percentage Breakdown of Value Sales for Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 67: France Current & Future Analysis for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 68: France Historic Review for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 69: France 15-Year Perspective for Autoimmune Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class for the Years 2012, 2020 & 2027
    • TABLE 70: France Current & Future Analysis for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 71: France Historic Review for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 72: France 15-Year Perspective for Autoimmune Disease Therapeutics by Indication - Percentage Breakdown of Value Sales for Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 73: Germany Current & Future Analysis for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Germany Historic Review for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 75: Germany 15-Year Perspective for Autoimmune Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class for the Years 2012, 2020 & 2027
    • TABLE 76: Germany Current & Future Analysis for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 77: Germany Historic Review for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 78: Germany 15-Year Perspective for Autoimmune Disease Therapeutics by Indication - Percentage Breakdown of Value Sales for Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 79: Italy Current & Future Analysis for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Italy Historic Review for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 81: Italy 15-Year Perspective for Autoimmune Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class for the Years 2012, 2020 & 2027
    • TABLE 82: Italy Current & Future Analysis for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Italy Historic Review for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 84: Italy 15-Year Perspective for Autoimmune Disease Therapeutics by Indication - Percentage Breakdown of Value Sales for Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 85: UK Current & Future Analysis for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 86: UK Historic Review for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 87: UK 15-Year Perspective for Autoimmune Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class for the Years 2012, 2020 & 2027
    • TABLE 88: UK Current & Future Analysis for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 89: UK Historic Review for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 90: UK 15-Year Perspective for Autoimmune Disease Therapeutics by Indication - Percentage Breakdown of Value Sales for Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027
  • SPAIN
    • TABLE 91: Spain Current & Future Analysis for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Spain Historic Review for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 93: Spain 15-Year Perspective for Autoimmune Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class for the Years 2012, 2020 & 2027
    • TABLE 94: Spain Current & Future Analysis for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Spain Historic Review for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 96: Spain 15-Year Perspective for Autoimmune Disease Therapeutics by Indication - Percentage Breakdown of Value Sales for Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027
  • RUSSIA
    • TABLE 97: Russia Current & Future Analysis for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Russia Historic Review for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 99: Russia 15-Year Perspective for Autoimmune Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class for the Years 2012, 2020 & 2027
    • TABLE 100: Russia Current & Future Analysis for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Russia Historic Review for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 102: Russia 15-Year Perspective for Autoimmune Disease Therapeutics by Indication - Percentage Breakdown of Value Sales for Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 103: Rest of Europe Current & Future Analysis for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Rest of Europe Historic Review for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 105: Rest of Europe 15-Year Perspective for Autoimmune Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class for the Years 2012, 2020 & 2027
    • TABLE 106: Rest of Europe Current & Future Analysis for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Rest of Europe Historic Review for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 108: Rest of Europe 15-Year Perspective for Autoimmune Disease Therapeutics by Indication - Percentage Breakdown of Value Sales for Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 109: Asia-Pacific Current & Future Analysis for Autoimmune Disease Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 110: Asia-Pacific Historic Review for Autoimmune Disease Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 111: Asia-Pacific 15-Year Perspective for Autoimmune Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
    • TABLE 112: Asia-Pacific Current & Future Analysis for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 113: Asia-Pacific Historic Review for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 114: Asia-Pacific 15-Year Perspective for Autoimmune Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class for the Years 2012, 2020 & 2027
    • TABLE 115: Asia-Pacific Current & Future Analysis for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 116: Asia-Pacific Historic Review for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 117: Asia-Pacific 15-Year Perspective for Autoimmune Disease Therapeutics by Indication - Percentage Breakdown of Value Sales for Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027
  • AUSTRALIA
    • TABLE 118: Australia Current & Future Analysis for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 119: Australia Historic Review for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 120: Australia 15-Year Perspective for Autoimmune Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class for the Years 2012, 2020 & 2027
    • TABLE 121: Australia Current & Future Analysis for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 122: Australia Historic Review for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 123: Australia 15-Year Perspective for Autoimmune Disease Therapeutics by Indication - Percentage Breakdown of Value Sales for Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027
  • INDIA
    • TABLE 124: India Current & Future Analysis for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 125: India Historic Review for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 126: India 15-Year Perspective for Autoimmune Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class for the Years 2012, 2020 & 2027
    • TABLE 127: India Current & Future Analysis for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 128: India Historic Review for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 129: India 15-Year Perspective for Autoimmune Disease Therapeutics by Indication - Percentage Breakdown of Value Sales for Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027
  • SOUTH KOREA
    • TABLE 130: South Korea Current & Future Analysis for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 131: South Korea Historic Review for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 132: South Korea 15-Year Perspective for Autoimmune Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class for the Years 2012, 2020 & 2027
    • TABLE 133: South Korea Current & Future Analysis for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 134: South Korea Historic Review for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 135: South Korea 15-Year Perspective for Autoimmune Disease Therapeutics by Indication - Percentage Breakdown of Value Sales for Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 136: Rest of Asia-Pacific Current & Future Analysis for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 137: Rest of Asia-Pacific Historic Review for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 138: Rest of Asia-Pacific 15-Year Perspective for Autoimmune Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class for the Years 2012, 2020 & 2027
    • TABLE 139: Rest of Asia-Pacific Current & Future Analysis for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 140: Rest of Asia-Pacific Historic Review for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 141: Rest of Asia-Pacific 15-Year Perspective for Autoimmune Disease Therapeutics by Indication - Percentage Breakdown of Value Sales for Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027
  • LATIN AMERICA
    • TABLE 142: Latin America Current & Future Analysis for Autoimmune Disease Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 143: Latin America Historic Review for Autoimmune Disease Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 144: Latin America 15-Year Perspective for Autoimmune Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
    • TABLE 145: Latin America Current & Future Analysis for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 146: Latin America Historic Review for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 147: Latin America 15-Year Perspective for Autoimmune Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class for the Years 2012, 2020 & 2027
    • TABLE 148: Latin America Current & Future Analysis for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 149: Latin America Historic Review for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 150: Latin America 15-Year Perspective for Autoimmune Disease Therapeutics by Indication - Percentage Breakdown of Value Sales for Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027
  • ARGENTINA
    • TABLE 151: Argentina Current & Future Analysis for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 152: Argentina Historic Review for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 153: Argentina 15-Year Perspective for Autoimmune Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class for the Years 2012, 2020 & 2027
    • TABLE 154: Argentina Current & Future Analysis for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 155: Argentina Historic Review for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 156: Argentina 15-Year Perspective for Autoimmune Disease Therapeutics by Indication - Percentage Breakdown of Value Sales for Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027
  • BRAZIL
    • TABLE 157: Brazil Current & Future Analysis for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 158: Brazil Historic Review for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 159: Brazil 15-Year Perspective for Autoimmune Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class for the Years 2012, 2020 & 2027
    • TABLE 160: Brazil Current & Future Analysis for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 161: Brazil Historic Review for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 162: Brazil 15-Year Perspective for Autoimmune Disease Therapeutics by Indication - Percentage Breakdown of Value Sales for Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027
  • MEXICO
    • TABLE 163: Mexico Current & Future Analysis for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 164: Mexico Historic Review for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 165: Mexico 15-Year Perspective for Autoimmune Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class for the Years 2012, 2020 & 2027
    • TABLE 166: Mexico Current & Future Analysis for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 167: Mexico Historic Review for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 168: Mexico 15-Year Perspective for Autoimmune Disease Therapeutics by Indication - Percentage Breakdown of Value Sales for Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027
  • REST OF LATIN AMERICA
    • TABLE 169: Rest of Latin America Current & Future Analysis for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 170: Rest of Latin America Historic Review for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 171: Rest of Latin America 15-Year Perspective for Autoimmune Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class for the Years 2012, 2020 & 2027
    • TABLE 172: Rest of Latin America Current & Future Analysis for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 173: Rest of Latin America Historic Review for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 174: Rest of Latin America 15-Year Perspective for Autoimmune Disease Therapeutics by Indication - Percentage Breakdown of Value Sales for Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027
  • MIDDLE EAST
    • TABLE 175: Middle East Current & Future Analysis for Autoimmune Disease Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 176: Middle East Historic Review for Autoimmune Disease Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 177: Middle East 15-Year Perspective for Autoimmune Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
    • TABLE 178: Middle East Current & Future Analysis for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 179: Middle East Historic Review for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 180: Middle East 15-Year Perspective for Autoimmune Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class for the Years 2012, 2020 & 2027
    • TABLE 181: Middle East Current & Future Analysis for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 182: Middle East Historic Review for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 183: Middle East 15-Year Perspective for Autoimmune Disease Therapeutics by Indication - Percentage Breakdown of Value Sales for Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027
  • IRAN
    • TABLE 184: Iran Current & Future Analysis for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 185: Iran Historic Review for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 186: Iran 15-Year Perspective for Autoimmune Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class for the Years 2012, 2020 & 2027
    • TABLE 187: Iran Current & Future Analysis for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 188: Iran Historic Review for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 189: Iran 15-Year Perspective for Autoimmune Disease Therapeutics by Indication - Percentage Breakdown of Value Sales for Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027
  • ISRAEL
    • TABLE 190: Israel Current & Future Analysis for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 191: Israel Historic Review for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 192: Israel 15-Year Perspective for Autoimmune Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class for the Years 2012, 2020 & 2027
    • TABLE 193: Israel Current & Future Analysis for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 194: Israel Historic Review for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 195: Israel 15-Year Perspective for Autoimmune Disease Therapeutics by Indication - Percentage Breakdown of Value Sales for Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027
  • SAUDI ARABIA
    • TABLE 196: Saudi Arabia Current & Future Analysis for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 197: Saudi Arabia Historic Review for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 198: Saudi Arabia 15-Year Perspective for Autoimmune Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class for the Years 2012, 2020 & 2027
    • TABLE 199: Saudi Arabia Current & Future Analysis for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 200: Saudi Arabia Historic Review for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 201: Saudi Arabia 15-Year Perspective for Autoimmune Disease Therapeutics by Indication - Percentage Breakdown of Value Sales for Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 202: UAE Current & Future Analysis for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 203: UAE Historic Review for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 204: UAE 15-Year Perspective for Autoimmune Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class for the Years 2012, 2020 & 2027
    • TABLE 205: UAE Current & Future Analysis for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 206: UAE Historic Review for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 207: UAE 15-Year Perspective for Autoimmune Disease Therapeutics by Indication - Percentage Breakdown of Value Sales for Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027
  • REST OF MIDDLE EAST
    • TABLE 208: Rest of Middle East Current & Future Analysis for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 209: Rest of Middle East Historic Review for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 210: Rest of Middle East 15-Year Perspective for Autoimmune Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class for the Years 2012, 2020 & 2027
    • TABLE 211: Rest of Middle East Current & Future Analysis for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 212: Rest of Middle East Historic Review for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 213: Rest of Middle East 15-Year Perspective for Autoimmune Disease Therapeutics by Indication - Percentage Breakdown of Value Sales for Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027
  • AFRICA
    • TABLE 214: Africa Current & Future Analysis for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 215: Africa Historic Review for Autoimmune Disease Therapeutics by Drug Class - Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 216: Africa 15-Year Perspective for Autoimmune Disease Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons and Other Drug Class for the Years 2012, 2020 & 2027
    • TABLE 217: Africa Current & Future Analysis for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 218: Africa Historic Review for Autoimmune Disease Therapeutics by Indication - Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 219: Africa 15-Year Perspective for Autoimmune Disease Therapeutics by Indication - Percentage Breakdown of Value Sales for Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease and Other Indications for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 138